Introduction 44
According to the World Health Organisation, more than 10% of people aged 60 and over suffer 45 from osteoarthritis worldwide 1 . Thereby it is the most common joint disease in this age range 46 2 . Over the last decades, numerous longitudinal studies on risk factors for onset of 47 osteoarthritis have been performed 3, 4 . These studies have led to the identification of a wide 48 variety of risk factors; mainly focusing on knee osteoarthritis. With this accumulated 49 knowledge, primary prevention should be considered 5, 6 . Several studies indicate that weight 50 loss in overweight or obese individuals could prevent knee osteoarthritis 3, [7] [8] [9] . In an 51 observational cohort, it was calculated that if women with a body mass index (BMI) ≥ 25 kg/m 2 52 would reduce their BMI with 2 units (~ 5 kg), the risk for developing knee osteoarthritis would 53 be reduced substantially (OR = 0.41) 8 . The direct effects of weight reduction (primary 54 prevention) on subsequent knee osteoarthritis development have never been studied. 55
Glucosamine has been studied for the treatment of osteoarthritis patients , but no 56 efficacy has been proven in studies with adequate allocation concealment or in investigator led 57 studies 10 . Literature suggests larger effects of glucosamine over placebo when used in an early 58 phase of the disease 11 and especially in the knee joint 12 . Glucosamine has never been tested 59 for its preventive effects. Since all forms of oral glucosamine have shown to produce no side 60 effects over placebo, even after long-term use 13 , investigation of the preventive effect of 61 glucosamine on incident knee osteoarthritis seems safe and worthwhile. 62
The objective of the present study was to evaluate the effect of a tailored diet and 63 7. interventions was assumed. Based on our previous 2-year osteoarthritis trial 25 , we accounted 130 for 10% lost to follow-up. Therefore, two groups of 200 subjects would be appropriate (one-131 sided testing, alpha = 0.05, beta = 0.80). 132
Statistical Analysis Intention To Treat (ITT) analyses on all available data of all knees of all 133 randomized participants served as primary analyses. The interaction between both 134 interventions was determined using Generalized Estimating Equations (GEE), adjusted for 135 confounding variables. Next, the effects of the diet and exercise program and the glucosamine 136 vs. placebo intervention were determined using GEE, adjusted for confounding variables. In 137 case of a significant interaction between the interventions, these analyses will be performed 138 over four groups, with subjects in the diet and exercise program control group receiving 139 placebo as reference (Appendix). 140
For the pre-defined Per Protocol (PP) analyses, the ITT analyses were rerun, between 141 those subjects compliant to the diet and exercise program (≥ 6 dietary consultations and ≥ 7 142 exercise classes) and those randomized to the control group and, separately, in those with an 143 objective compliance calculation ≥ 75% . A sensitivity analysis excluding all knees fulfilling one 144 of the criteria of the primary outcome at baseline was performed, and all analyses were 145 repeated on subject level. All analyses were performed using PASW statistics version 20.0 (SPSS 146
Inc., Chicago, IL). 147
Available secondary outcomes were analysed using a linear mixed model estimated by 148 restricted maximum likelihood (SAS 9.2, SAS Institute Inc., Cary, NC). A p-value < 0.05 was 149 defined as statistically significant for all analyses. Randomization code for glucosamine vs. 150 placebo intervention was broken after all analyses were completed. 151
Results

153
In total, 6691 women were contacted by fifty general practitioners. Eventually, 407 women 154 were invited for baseline measurements and were randomised (24.8% to the diet and exercise 155 program intervention/placebo group and 25.1% to each of the other groups, see Figure 1 ). 156
Mean age was 55.7 ± 3.2 years and mean BMI was 32.4 ± 4.3 kg/m 2 ( Table 1 ). After 2.5 years, 157 forty-one women (10.1%) were lost to follow-up. Of these, thirty-six women were unwilling; 158 two withdrew because of side effects; one was unattainable; two died in the course of the 159 study. One woman died shortly after study ending (all deaths not related to study drugs). 160
Joint space narrowing (ICC 0.67 -0.76) was found medially in 5% and laterally in 6% of all 161 knees. Incidence of K&L-grade ≥ 2 was found in 4% of all knees (kappa 0.6). Six per cent of all 162 knees showed incident clinical osteoarthritis. Combined into the primary outcome, 135 knees 163 (17%) showed incident knee osteoarthritis (in 28% of all women). Despite the fact that all 164 included subjects were free of clinical knee osteoarthritis at initial screening, 3.9% of all knees 165 fulfilled the ACR criteria at baseline and 6.6% showed K&L-grade 2 after detailed assessment of 166 the radiographs.. Multivariately, only K&L grade was associated with the primary outcome. 167
Intention To Treat Analyses
The ITT analyses showed a significant interaction (p = 0.04). Hence, 168 the effects of one intervention depended on the allocation of the other intervention and four 169 groups had to be analysed separately ( Table 2) . control group. At 6 and 12 months, the number of participants fulfilling the predefined target of 174 5 kg or 5% weight reduction was significantly higher in the intervention group (14% vs. 6% at 6 175 months, p = 0.01; 17% vs. 10% at 12 months, p = 0.04). Eventually, 63 women (15%) met this 176 target at 30 months. Detailed effects of the diet and exercise program can be found elsewhere 177
. 178
PP analyses showed a significant interaction with the glucosamine vs. placebo 179 intervention (p = 0.01). Incidence of knee osteoarthritis was found in 19%, 13%, 9% and 23% of 180 the knees of subjects randomized to the control group with placebo, with glucosamine, subjects 181 compliant to the diet and exercise program with placebo and those with glucosamine, 182 respectively (Table 3) . 183
Oral Glucosamine Sulphate versus Placebo A total of 291 adverse events were reported by a 184 total of 118 women, equally divided between glucosamine and placebo group (Chi 2 test: p = 185 0.23). All reported serious adverse events (26 by 25 women) were classified as not related to 186 study drug and also equally divided between groups (Chi 2 test: p = 0.26). After study ending, 187 17% of the women in the placebo group and 15% of the women in the glucosamine group were 188 convinced they had received glucosamine. The majority of all women (52% in the placebo group 189 and 46% in the glucosamine group) were convinced they received placebo (Chi 2 test: p = 0.24). 190
None of the involved researchers or participants were unblinded during the trial. In total, 250 191 women were compliant (66% of the placebo group, 57% of the glucosamine group). This study presents the first ever preventive randomized trial on osteoarthritis 215
worldwide. The diet and exercise program and the glucosamine sulphate intervention showed 216 no significant main effects on the incidence of knee osteoarthritis after 2.5 years. However, due 217
11.
to the unexpected significant interaction, these analyses were slightly underpowered. The fact 218 that the interaction became even stronger in subjects compliant to the diet and exercise 219 program, was found in sensitivity analyses, and at subject level, indicates a true interaction 220 between the interventions. 221
This preventive randomised trial focused on subjects with high risk of developing knee 222 osteoarthritis and used a combined outcome measure to make a trial in such a slowly 223 progressing disease feasible over a relative short time period. This combination of radiographic 224 and clinical measures of knee osteoarthritis into the primary outcome improves the ability to 225 determine the preventive effects of the studied interventions 5 , although one misses the 226 detailed insight in the development of the disease. Explorative evaluation of the separate items 227 of the primary outcome confirmed the pattern found in the main analyses, but longer follow-up 228 is needed to statistically test these outcomes separately given the naturally slow disease 229
development. 230
Although we found no significant main effects of the diet and exercise program and the 231 glucosamine vs. placebo intervention on primary outcomes, the interaction between the 232 interventions did show several interesting results. Where glucosamine sulphate reduced 233 osteoarthritis incidence numbers in the group not undergoing the diet and exercise program 234 and co-workers found that after a 6 months exercise period, subjects randomized to a 245 combination of glucosamine/chondroitin decreased in knee flexion strength, whereas subjects 246 receiving placebo significantly improved their strength 26 . These results suggest that 247 glucosamine might interfere with processes of repair and growth after physical exercise. On the 248 other hand, a 12 week training program combined with glucosamine sulphate did not show a 249 difference in knee extension strength over the placebo group in knee osteoarthritis patients 27 . 250
The more sensitive and explorative measures of the MRI and biomarkers, which are being 251 assessed within the present study, might provide more detailed information on the underlying 252
mechanism. 253
For implementation reasons, a very pragmatic design was chosen for the diet and 254 exercise program. Nevertheless, the intervention had a significant effect on the actual weight 255 loss during the first year of follow-up and activity levels were higher in the intervention group 256 throughout the total follow-up period. Thus, despite the relatively low compliance figures, 257 similar to other physical exercise and diet interventions in overweight and obese individuals 28 , 258 and a short duration, the current diet and exercise program succeeded in a low level change in 259 lifestyle, also in the ITT population. Contrary to daily practice, the control group was relatively 260 active . Nearly 90% of all subjects stated to have a preference for the intervention group at 261 13.
baseline. For ethical reasons, the control group was not actively refrained from any 262 interventions on weight loss. After 2.5 years, 18% of all women randomized to the control 263 group fulfilled the criterion of losing 5 kg or 5% of baseline body weight. Therefore, the effects 264 of the diet and exercise program found on incident knee osteoarthritis may have been 265
underestimated. 266
In conclusion, we showed no significant main effects of the diet and exercise program or 267 the glucosamine vs. placebo intervention on incidence of knee osteoarthritis over 2.5 years. 268
These analyses, however, were hampered by an unexpected significant interaction between the 269 two interventions. The current trial provides many new insights in the possibilities for 270 prevention of knee osteoarthritis within a high-risk group of middle-aged, overweight women. 
1.
The * unadjusted odds ratio. ** odds ratio adjusted for baseline KL grade (0 vs. ≥ 1). DEP: diet and exercise program, OR: odds ratio, CI: confidence interval.
APPENDIX to 'Prevention of knee osteoarthritis in overweight females; the first randomized controlled trial in OA'osteoarthritis'.
Additional method section
Setting and Participants Fifty general practitioners in the region of Rotterdam, The Netherlands, sent study information and a reply-card to all registered women between 50 and 60 years without major co-morbidities.
Interested women with a reported BMI ≥ 27 kg/m 2 were contacted by phone to check all inclusion criteria.
Besides age and BMI-related inclusion criteria, subjects had to be free of knee OA osteoarthritis according to the clinical American College of Rheumatology (ACR)-criteria 1 , not under treatment for knee complaints, free of MRI contraindications, free of rheumatic diseases, not using walking-aids, master the Dutch language and not using oral glucosamine for the last 6 months.
Radiography Semi-flexed posterior-anterior knee radiographs were taken at baseline and follow-up according to the MTP protocol 
Sample Size
The study was powered to show an incidence reduction from 20% in the DEP diet and exercise program control group and in the placebo group to 10% in the diet and exercise program DEP intervention and the glucosamine group. These numbers were based on a twelve year follow-up study with an overall incidence of K&L ≥ 2 of 39.1% in subject with a BMI ≥ 26.4 kg/m 2 6 . In the present age group, this number was 1.6 fold higher, suggesting an incidence of 13% over 2.5 years. The primary outcome combined incidence of K&L grade ≥ 2, ACR criteria and JSN. Since there is only moderate overlap between these measures , mild knee symptoms ('Did you experience knee pain in the past 12 months'), BMI, a history of knee injury, Heberden´s nodes, and postmenopausal status) and the primary outcome was determined using Generalized Estimating Equations (GEE), with the association between two knees within one person taken into account. Variables with a p-value < 0.2 were analysed multivariately. Variables with a p-value <0.05 in the multivariate model were adopted as confounders. Second, the interaction between both interventions was determined using GEE, adjusted for the confounding variables.
Third, the effects of diet and exercise program DEP and GSvP the glucosamine vs. placebo intervention were determined using GEE, adjusted for the confounding variables. In case of a significant interaction between the interventions, these analyses will be performed over four groups, with subjects in the diet and exercise program DEP control group receiving placebo as reference group.
For the pre-defined Per Protocol (PP) analyses, the latter two ITT analyses were rerun, between those subjects compliant to DEP the diet and exercise program (≥ 6 dietary consultations and ≥ 7 attended physical exercise classes) and those randomized to the DEP control group and, separately, in those with an objective compliance calculation ≥ 75% of the study drug throughout the study period. A sensitivity analysis excluding all knees fulfilling one of the criteria of the primary outcome at baseline was performed, and finally all analyses were repeated on a subject level. All analyses were performed using PASW statistics version 20.0 (SPSS Inc., Chicago, IL).
Available secondary outcomes were analysed using a linear mixed model estimated by restricted maximum likelihood (REML) to test effects of both interventions and their interaction over the follow-up period (SAS 9.2, SAS Institute Inc., Cary, NC). A p-value < 0.05 was defined as statistically significant for all analyses.
Randomization code for GSvP glucosamine vs. placebo intervention was broken after all analyses were completed. 
